- Home
- BMEA vs GMGI Comparison
BMEA vs GMGI Comparison
Compare BMEA & GMGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- GMGI
- Stock Information
- Founded
- BMEA 2017
- GMGI 2008
- Country
- BMEA United States
- GMGI United States
- Employees
- BMEA N/A
- GMGI N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- GMGI Computer Software: Prepackaged Software
- Sector
- BMEA Health Care
- GMGI Technology
- Exchange
- BMEA Nasdaq
- GMGI Nasdaq
- Market Cap
- BMEA 125.0M
- GMGI 145.9M
- IPO Year
- BMEA 2021
- GMGI N/A
- Fundamental
- Price
- BMEA $1.66
- GMGI $0.98
- Analyst Decision
- BMEA Strong Buy
- GMGI Strong Buy
- Analyst Count
- BMEA 8
- GMGI 1
- Target Price
- BMEA $10.63
- GMGI $4.00
- AVG Volume (30 Days)
- BMEA 3.1M
- GMGI 228.4K
- Earning Date
- BMEA 10-28-2025
- GMGI 11-12-2025
- Dividend Yield
- BMEA N/A
- GMGI N/A
- EPS Growth
- BMEA N/A
- GMGI N/A
- EPS
- BMEA N/A
- GMGI N/A
- Revenue
- BMEA N/A
- GMGI $172,818,124.00
- Revenue This Year
- BMEA N/A
- GMGI $25.43
- Revenue Next Year
- BMEA N/A
- GMGI $13.00
- P/E Ratio
- BMEA N/A
- GMGI N/A
- Revenue Growth
- BMEA N/A
- GMGI 54.66
- 52 Week Low
- BMEA $1.29
- GMGI $0.91
- 52 Week High
- BMEA $12.85
- GMGI $3.06
- Technical
- Relative Strength Index (RSI)
- BMEA 41.51
- GMGI 37.10
- Support Level
- BMEA $1.66
- GMGI $0.96
- Resistance Level
- BMEA $2.99
- GMGI $1.16
- Average True Range (ATR)
- BMEA 0.19
- GMGI 0.08
- MACD
- BMEA -0.06
- GMGI -0.00
- Stochastic Oscillator
- BMEA 3.96
- GMGI 7.50
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About GMGI Golden Matrix Group Inc.
Golden Matrix Group Inc is an established gaming technology company. The company develops and owns online gaming IP and builds configurable and scalable white-label social gaming platforms for its international customers. The company operates in three reportable segments; MeridianBet Group, GMAG, RKings & CFAC. The MeridianBet Group segment earns majority revenue. The company operates in UK, Europe, Asia Pacific, Central and South America, Australia and Africa. It offers configurable and scalable iGaming platforms and operate some of the industry's iconic brands, including MexPlay, GM-AG, and others.